CEPHEUS FDA Approval: Daratumumab and Hyaluronidase-fihj Plus VRd for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with...
